Imunon, Inc. Expected to Earn FY2028 Earnings of ($0.32) Per Share (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNNFree Report) – HC Wainwright issued their FY2028 earnings estimates for Imunon in a research note issued to investors on Monday, April 1st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.32) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Imunon’s current full-year earnings is ($1.95) per share.

Imunon Trading Down 9.3 %

Shares of IMNN opened at $1.75 on Tuesday. The stock has a market cap of $16.45 million, a P/E ratio of -0.80 and a beta of 2.02. The company has a 50-day moving average of $0.81 and a two-hundred day moving average of $0.87. Imunon has a 12-month low of $0.48 and a 12-month high of $2.00.

Hedge Funds Weigh In On Imunon

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its holdings in shares of Imunon by 20.1% during the second quarter. Renaissance Technologies LLC now owns 74,011 shares of the company’s stock worth $95,000 after buying an additional 12,400 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Imunon during the first quarter worth about $83,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Imunon during the first quarter worth about $62,000. Institutional investors and hedge funds own 4.47% of the company’s stock.

About Imunon

(Get Free Report)

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.

Further Reading

Earnings History and Estimates for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with's FREE daily email newsletter.